Mobility Promotion for Cardiovascular Disease
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Mobility promotion for cardiovascular disease?
Is mobility promotion generally safe for humans?
How does the mobility promotion treatment for cardiovascular disease differ from other treatments?
The mobility promotion treatment for cardiovascular disease is unique because it focuses on increasing physical activity as a way to improve heart health, rather than relying on medication. This approach emphasizes the benefits of simply moving more, which can lead to better health outcomes even with modest increases in activity.1112131415
What is the purpose of this trial?
Frailty describes the overall health of a person. Inpatients with cardiovascular problems have a higher risk for frailty - or the sick are more likely to get sicker - causing longer hospital stays, hospital readmission, and death. Females are particularly vulnerable to these problems, generally displaying higher frailty levels than males. In hospital, patients spend almost all their time in bed, and this lack of movement worsens cardiovascular and musculoskeletal health, sometimes lengthening patients' hospital stay and priming them for another cardiovascular event. Prolonged sedentary time may be more detrimental on frailty among females than males. The proposed pilot project will test if an in-hospital General Medicine mobilization program reduces frailty (measure of overall health) in male and female inpatients with cardiovascular disease. A Kinesiologist will provide daily check-ins and promote daily movement (e.g., standing more, resistance bands, physical activity promotion, etc.). The investigators expect both males and females will lower their frailty levels, but given their higher frailty levels in general and because females are typically less active than males, the investigators expect the intervention's effects to be greatest among females. Sixty patients (30 females) will be recruited. Patients with a major heart problem, projected to be in-hospital for at least 3-days, and can independently provide consent. Frailty will be measured using a validated questionnaire. Participants will also be equipped with activity monitors for 24h/d continuous wear to measure amount of time spent stepping, sitting, and lying. Hospital records will be used for length of stay and readmissions. The investigators will compare the outcomes (activity and frailty) between males and females to determine if the intervention impacted each sex differently. This work will guide improved care plans to decrease frailty and improve health outcomes in both male and female patients with heart problems.
Eligibility Criteria
This trial is for male and female inpatients with cardiovascular disease who are at risk of frailty. Participants must have a major heart problem, be expected to stay in the hospital for at least 3 days, and be able to give consent independently. The study aims to include 60 patients (30 females).Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a mobilization program with daily check-ins by a Kinesiologist to promote movement and reduce frailty
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Mobility promotion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Université de Sherbrooke
Lead Sponsor
Vitalite Health Network
Collaborator